Theia Life Sciences

Theia Biosciences is a biotechnology company dedicated to developing innovative therapies for retinal diseases, with a primary focus on geographic atrophy (GA) and age-related macular degeneration (AMD). The company was founded by the former executive leadership team of Iveric Bio, including Glenn Sblendorio and Pravin Dugel, following the acquisition of Iveric by Astellas Pharma. Theia Biosciences targets the HtrA1 (High-temperature requirement A1) pathway, a genetically validated driver of GA, to develop next-generation treatments that aim to preserve vision. The company operates as part of the broader Theia Life Sciences ecosystem, which includes strategic advisory and investment arms. Currently in the pre-clinical stage, Theia is leveraging its founders' extensive experience in ophthalmic drug development to advance its pipeline toward clinical trials.